# Ecolab Inc.: Form 10-Q for the period ended Sep 30, 2020

- Company: [Ecolab Inc.](/companies/ecl.md) (CIK 31462)
- Form: 10-Q
- Filed: 2020-10-30
- Accepted by EDGAR: Oct 30, 2020, 07:32 ET
- Period: 2020-09-30
- Accession: 0001558370-20-012094
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/31462/000155837020012094/ecl-20200930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/31462/000155837020012094/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $3.02bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-01 to 2020-09-30 | $8.72bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-07-01 to 2020-09-30 | $1.77bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-01 to 2020-09-30 | $5.13bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2020-07-01 to 2020-09-30 | $802.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-09-30 | $2.50bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | $411.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | $979.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $139.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $253.4m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-07-01 to 2020-09-30 | $42.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-09-30 | $103.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | $249.3m | us-gaap:ProfitLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | −$1.49bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.85 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-30 | −$5.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.86 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-09-30 | −$5.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-01 to 2020-09-30 | 288,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-09-30 | 290,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | $1.21bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-30 | $362.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2020-01-01 to 2020-09-30 | $421.8m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2020-01-01 to 2020-09-30 | $124.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-09-30 | $1.03bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $4.99bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $18.10bn | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $3.11bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $12.05bn | us-gaap:Liabilities |
| Current portion of debt | at 2020-09-30 | $247.3m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2020-09-30 | $6.01bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2020-09-30 | 285,445,183 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 91,012 characters.

The following management discussion and analysis (“MD&A”) provides information we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The MD&A should be read in conjunction with both the unaudited consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2019. This discussion contains various Non-GAAP Financial Measures and also contains various Forward-Looking Statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Statements” located at the end of Part I of this report.

### Comparability of Results

### ChampionX Transaction

On June 3, 2020, we completed the previously announced separation of its Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX Business, followed immediately by the merger of ChampionX (the “Merger”) with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

The ChampionX business met the criteria to be reported as discontinued operations because it is a strategic shift in business that has a major effect on our operations and financial results. Therefore, we report the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein. Unless otherwise noted, the accompanying MD&A has been revised to reflect the ChampionX business as discontinued operations and all prior year balances have been revised accordingly to reflect continuing operations only.

### Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

### Comparability of Reportable Segments

Effective in the first quarter of 2020, and in anticipation of the separation of the Upstream Energy business, we created the Upstream and Downstream operating segments and reporting units from the Global Energy operating segment and reporting unit, which was also a reportable segment. The Downstream operating segment, which was previously included in the Global Energy reportable segment has been aggregated into the Global Industrial reportable segment. The table below reflects the elimination of the Global Energy reportable segment and creation of the Downstream operating segment. Also, in the first quarter of 2020, we announced leadership changes which allow for shared oversight and focus on the Healthcare and Life Sciences operating segments and established the Global Healthcare & Life Sciences reportable segment. This segment is comprised of the Healthcare operating segment which was previously aggregated in the Global Institutional reportable segment and the Life Sciences operating segment which was previously aggregated in the Global Industrial reportable segment. Additionally, the Textile Care operating segment being reported in Other, which had previously been aggregated in the Global Industrial reportable segment. We also renamed the Global Institutional reportable segment to the Global Institutional & Specialty reportable segment. We made other immaterial changes, including the movement of certain customers and cost allocations between reportable segments.

### Impact of Acquisitions and Divestitures

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of our divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These sales are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

### CRITICAL ACCOUNTING ESTIMATES

In our report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 28, 2020, we disclosed our Critical Accounting Estimates. The discussion below provides an update to the Critical Accounting Estimates and should be read together with the full list of Critical Accounting Estimates set forth in the aforementioned Form 10-K.

### Goodwill

We had total goodwill of $6.0 billion and $5.6 billion as of September 30, 2020 and December 31, 2019, respectively. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. Our reporting units are our operating segments. We assess goodwill for impairment on an annual basis during the second quarter. If circumstances change significantly, we would complete an interim goodwill assessment of a reporting unit’s goodwill prior to its next annual assessment.

During the second quarter of 2020, we completed our annual goodwill impairment assessment for each of its eleven reporting units using quantitative analyses consisting of discounted cash flow approaches that incorporated assumptions regarding future growth rates, terminal values, and discount rates. If the carrying value of a reporting unit is greater than its fair value, we will recognize an impairment loss for the amount by which the reporting unit’s carrying value exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit. Our goodwill impairment assessment for 2020 indicated the estimated fair values of each of its reporting units exceeded their carrying amounts by significant margins.

### OVERVIEW OF THE THIRD QUARTER ENDED SEPTEMBER 30, 2020

### Sales Performance

When comparing third quarter 2020 against third quarter 2019, sales performance was as follows:

- Reported net sales decreased 6% to $3,019 million, fixed currency sales and acquisition adjusted fixed currency sales decreased 6% and 8%, respectively.
- Fixed currency sales for our Global Industrial segment decreased 2% to $1,491 million, acquisition adjusted fixed currency sales decreased 3%, as modest growth in Food & Beverage was more than offset by lower volumes in the other Industrial businesses.
- Fixed currency sales for our Global Institutional & Specialty segment decreased 22% to $901 million. Acquisition adjusted fixed currency sales also decreased 22%, driven by a significant decline in the in the Institutional business, where continued strong sanitizing product sales were more than offset by significantly reduced restaurant, lodging and entertainment facility demand due to the COVID-19 pandemic’s impact on travel and dining.
- Fixed currency sales for our Global Healthcare & Life Sciences segment increased 32% to $321 million. Acquisition adjusted fixed currency sales increased 29%, driven by increased sales due to the COVID-19 related demand in both the Healthcare and Life Sciences businesses.
- Fixed currency sales and acquisition adjusted fixed currency sales for Other decreased 12% to $286 million, primarily reflecting significantly reduced Textile Care demand.

### Financial Performance

When comparing third quarter 2020 against third quarter 2019, our financial performance was as follows:

- Reported operating income decreased 25% to $411 million. Excluding the impact of special (gains) and charges from both 2020 and 2019 reported results, adjusted operating income decreased 22% and our adjusted fixed currency operating income decreased 22%.
- Net income from continuing operations attributable to Ecolab decreased 44% to $246 million. Excluding the impact of special (gains) and charges and discrete tax items from both 2020 and 2019 reported results, our adjusted net income from continuing operations attributable to Ecolab decreased 26%.
- Reported diluted EPS from continuing operations of $0.85 decreased 43%. Excluding the impact of special (gains) and charges and discrete tax items from both 2020 and 2019 reported results, adjusted diluted EPS from continuing operations decreased 24% to $1.15 in the third quarter of 2020.
- Our reported tax rate was 14.5% during the third quarter of 2020, compared to 15.9% during the third quarter of 2019. Excluding the tax rate impact of special (gains) and charges and discrete tax items from both 2020 and 2019 results, our adjusted tax rate was 20.0% during the third quarter of 2020, compared to 19.6% during the third quarter of 2019.

### RESULTS OF OPERATIONS

### Net Sales

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ ​ | ​ ​ Change | ​ ​ ​ ​ | ​ ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ ​ | ​ ​ Change | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- |
| Product and equipment sales | ​ | **​** | **$2,426.4** | **​** | ​ | ​ | $2,591.8 | ​ | **​** **​** | **​** | ​ | **​** | **$7,017.5** | **​** | ​ | ​ | $7,511.6 | ​ | **​** **​** | ​ |
| Service and lease sales | ​ | **​** | **592.2** | **​** | ​ | ​ | 632.2 | ​ | **​** **​** | **​** | ​ | **​** | **1,707.4** | **​** | ​ | ​ | 1,806.2 | ​ | **​** **​** | ​ |
| Reported GAAP net sales | ​ | **​** | **$3,018.6** | **​** | ​ | ​ | $3,224.0 | ​ | **(6)%** | **​** | ​ | **​** | **$8,724.9** | **​** | ​ | ​ | $9,317.8 | ​ | **(6)%** | ​ |
| Effect of foreign currency translation | ​ |  | **28.6** | **​** | ​ | ​ | 10.7 | ​ | **​** **​** | **​** | ​ |  | **127.1** | **​** | ​ | ​ | 8.0 | ​ | **​** **​** | ​ |
| Non-GAAP fixed currency sales | ​ | **​** | **$3,047.2** | **​** | ​ | ​ | $3,234.7 | ​ | **(6)%** | **​** | ​ | **​** | **$8,852.0** | **​** | ​ | ​ | $9,325.8 | ​ | **(5)%** | ​ |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ |

Product and sold equipment revenue is generated from providing cleaning, sanitizing and water treatment products or selling equipment used in combination with specialized products. Service and lease equipment revenue is generated from providing services or leasing equipment to customers. All of our sales are subject to the same economic conditions.

The percentage components of the period-over-period 2020 sales change are shown below:

| ​ ​ ​ ​ ​ ​ ​ ​ (percent) | ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2020 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Nine Months Ended September 30 2020 |
| --- | ---: | --- | ---: |
| Volume | **(9)%** | **​** | **(8)%** |
| Price changes | **1** **​** | **​** | **2** **​** |
| Acquisition adjusted fixed currency sales change | **(8)** **​** | **​** | **(7)** **​** |
| Acquisitions and divestitures | **2** **​** | **​** | **2** **​** |
| Fixed currency sales change | **(6)** **​** | **​** | **(5)** **​** |
| Foreign currency translation | **(1)** **​** | **​** | **(1)** **​** |
| Reported GAAP net sales change | **(6)%** | **​** | **(6)%** |

Amounts do not necessarily sum due to rounding.

### Cost of Sales (“COS”) and Gross Profit Margin

| ​ ​ ​ ​ ​ (millions/percent) | ​ Third Quarter Ended September 30 2020 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2019 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ ​ ​ | ​ Nine Months Ended September 30 2020 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2019 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin |
| --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Product and equipment cost of sales | ​ | **$1,405.4** | ​ | ​ | **​** **​** | ​ | ​ | $1,413.0 | ​ | ​ | ​ ​ | ​ | ​ | **$4,071.6** | ​ | ​ | **​** **​** | ​ | ​ | $4,175.7 | ​ | ​ | ​ ​ |
| Service and lease cost of sales | ​ | **364.2** | ​ | ​ | **​** **​** | ​ | ​ | 367.9 | ​ | ​ | ​ ​ | ​ | ​ | **1,053.9** | ​ | ​ | **​** **​** | ​ | ​ | 1,061.0 | ​ | ​ | ​ ​ |
| Reported GAAP COS and gross margin | ​ | **$1,769.6** | ​ | ​ | **41.4%** | ​ | ​ | $1,780.9 | ​ | ​ | 44.8% | ​ | ​ | **$5,125.5** | ​ | ​ | **41.3%** | ​ | ​ | $5,236.7 | ​ | ​ | 43.8% |
| Special (gains) and charges | ​ | **9.5** | ​ |  | **​** **​** | ​ | ​ | 11.4 | ​ |  | ​ ​ | ​ | ​ | **45.6** | ​ |  | **​** **​** | ​ | ​ | 22.8 | ​ |  | ​ ​ |
| Non-GAAP adjusted COS and gross margin | **​** | **$1,760.1** | ​ | ​ | **41.7%** | ​ | ​ | $1,769.5 | ​ | ​ | 45.1% | ​ | **​** | **$5,079.9** | ​ | ​ | **41.8%** | ​ | ​ | $5,213.9 | ​ | ​ | 44.0% |

Our COS and corresponding gross profit margin (“gross margin”) are shown in the table above. Gross margin is defined as net sales less cost of sales divided by net sales.

Our reported gross margin was 41.4% and 44.8% for the third quarter of 2020 and 2019, respectively. Our reported gross margin for the first nine months of 2020 and 2019 was 41.3% and 43.8%, respectively. Special (gains) and charges included in items impacting COS are shown within the “Special (Gains) and Charges” table on page 39.

Excluding the impact of special (gains) and charges within COS, third quarter 2020 adjusted gross margin was 41.7% and our adjusted gross margin for the first nine months of 2020 was 41.8%. These percentages compared against a third quarter 2019 adjusted gross margin of 45.1% and an adjusted gross margin of 44.0% for the first nine months of 2019.

Our adjusted gross margin decreased when comparing the third quarter of 2020 against the third quarter of 2019 and decreased compared to the first nine months of 2020 and 2019, which was driven primarily by lower volume leverage and unfavorable business mix which more than offset the benefits of pricing.

### Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expenses as a percentage of sales were 26.6% and 28.6% for the third quarter and first nine months of 2020, respectively, compared to 27.0% and 28.6% for the third quarter and first nine months of 2019, respectively. The third quarter SG&A ratio to sales decreased due to lower discretionary spending, lower incentive compensation and cost saving initiatives. SG&A as a ratio to sales was flat for the first nine months of 2020 compared to the first nine months of 2019 as the impact of lower sales offset the benefits from lower incentive compensation, lower discretionary spending and cost savings initiatives.

### Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statement of Income include the following items:

| ​ ​ ​ ​ (millions) Cost of sales | ​ ​ ​ ​ ​ | ​ ​ Third Quarter Ended September 30 2020 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ 2019 ​ | ​ ​ ​ | ​ ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30 2020 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ 2019 ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Restructuring activities | ​ | **​** | **$1.0** | ​ | ​ | ​ | $6.3 | ​ | **​** | **$6.6** | ​ | ​ |  | $16.2 | ​ |
| Acquisition and integration activities | ​ | **​** | **1.5** | ​ | ​ | ​ | 5.1 | ​ | ​ | **4.1** | ​ | ​ | ​ | 6.6 | ​ |
| Other | ​ | **​** | **7.0** | ​ | ​ | ​ | - | ​ | **​** | **34.9** | ​ | ​ | ​ | - | ​ |
| Cost of sales subtotal | ​ | **​** | **9.5** | ​ | ​ | ​ | 11.4 | ​ | **​** | **45.6** | ​ | ​ |  | 22.8 | ​ |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Special (gains) and charges | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Restructuring activities | ​ | **​** | **26.9** | ​ | ​ | ​ | 19.3 | ​ | **​** | **31.4** | ​ | ​ |  | 70.2 | ​ |
| Acquisition and integration activities | ​ | **​** | **2.7** | ​ | ​ | ​ | 2.0 | ​ | **​** | **5.5** | ​ | ​ | ​ | 4.9 | ​ |
| Disposal and impairment activities | ​ | **​** | **-** | ​ | ​ | ​ | - | ​ | **​** | **45.9** | ​ | ​ | ​ | - | ​ |
| Other | ​ | **​** | **5.4** | ​ | ​ | ​ | 3.6 | ​ | **​** | **37.5** | ​ | ​ |  | 13.7 | ​ |
| Special (gains) and charges subtotal | ​ | **​** | **35.0** | ​ | ​ | ​ | 24.9 | ​ | **​** | **120.3** | ​ | ​ |  | 88.8 | ​ |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Operating income subtotal | ​ | **​** | **44.5** | ​ | ​ | ​ | 36.3 | ​ | **​** | **165.9** | ​ | ​ | ​ | 111.6 | ​ |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Interest expense, net | ​ | **​** | **83.1** | ​ | ​ | ​ | - | ​ | **​** | **83.8** | ​ | ​ | ​ | 0.2 | ​ |
| Total special (gains) and charges | ​ | **​** | **$127.6** | **​** | ​ | ​ | $36.3 | ​ | **​** | **$249.7** | **​** | **​** | ​ | $111.8 | ​ |

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

### Restructuring activities

Restructuring activities are primarily related to Accelerate 2020 (described below). These activities and related costs have been included as a component of cost of sales and special (gains) and charges on the Consolidated Statement of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheet. Restructuring charges directly related to the ChampionX business were recorded as discontinued operations, refer to Note 4.

#### Accelerate 2020

During the third quarter of 2018, we formally commenced a restructuring plan Accelerate 2020 (“the Plan”), to leverage technology and system investments and organizational changes. The goals of the Plan is to further simplify and automate processes and tasks, reduce complexity and management layers, consolidated facilitates and focus on key long-term growth areas by further leveraging technology and structural improvements. In the third quarter of 2020, we expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. We now expect that the restructuring activities will be completed by the end of 2022, with total anticipated costs of $275 million ($210 million after tax), or $0.72 per diluted share, over this period of time. Costs are expected to be primarily cash expenditures for severance costs and some facility closure costs relating to team reorganizations. Actual costs may vary from these estimates depending on actions taken.

We recorded restructuring charges of $27.9 million ($21.2 million after tax), or $0.07 per diluted share and $37.0 million (28.9 million after tax), or $0.10 per diluted share in the third quarter and first nine months of 2020, respectively. The liability related to the Plan was $87.4 million as of the end of the third quarter of 2020. We have recorded $243.5 million ($187.5 million after tax), or $0.65 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters and continues to be funded from operating activities. The remaining liability is expected to be paid over a period of several quarters and will continue to be funded from operating activities. Cash payments during 2020 related to the Plan were $45.3 million.

The Plan has delivered $181 million of cumulative cost savings with estimated annual cost savings of $335 million in continuing operations by 2022.

#### Other Restructuring Activities

During the first nine months of 2020, we incurred restructuring charges of $1.0 million ($0.6 million after tax), or less than $0.01 per diluted share, none of which was incurred during the third quarter, related to an immaterial restructuring plan. The charges primarily related to severance. Prior to 2018, we engaged in a number of restructuring plans. During the third quarter and first nine months of 2020 and 2019, net restructuring charges related to prior year plans were minimal. The restructuring liability balance for all plans commencing prior to 2018 was $6.1 million and $7.7 million as of September 30, 2020 and December 31, 2019, respectively. The reduction in liability was driven primarily by severance payments. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

Cash payments during 2020 related to all other restructuring plans excluding Accelerate 2020 were $2.5 million.

### Acquisition and integration related costs

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statement of Income include $2.7 million ($2.3 million after tax) or less than $0.01 per diluted share, and $5.5 million ($4.3 million after tax) or $0.01 per diluted share, in the third quarter and first nine months of 2020, respectively. Charges are related to Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), Bioquell PLC (“Bioquell”) and the Laboratoires Anios (“Anios”) acquisitions and consist of integration costs, advisory and legal fees, and hedge activity. Acquisition and integration costs reported in product and equipment cost of sales of $1.5 million ($1.3 million after tax) or less than $0.01 per diluted share, and $4.1 million ($3.2 million after tax) or $0.01 per diluted share in the third quarter and first nine months of 2020, respectively, on the Consolidated Statement of Income relate to the recognition of fair value step-up in the CID Lines inventory, severance and the closure of a facility. We also incurred $0.7 million ($0.6 million after tax) or less than $0.01 per diluted share in the first nine months of 2020, none of which was incurred during the third quarter.

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statement of Income include $2.0 million ($1.5 million after tax) or less than $0.01 per diluted share, and $4.9 million ($3.6 million after tax) or $0.01 per diluted share, in the third quarter and first nine months of 2019, respectively. Charges are related to Bioquell and the Anios acquisitions and consist of integration costs, advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales of $5.1 million ($3.8 million after tax) or $0.01 per diluted share, and $6.6 million ($4.9 million after tax) or $0.02 per diluted share, on the Consolidated Statement of Income in the third quarter and first nine months of 2019, respectively, relate to the recognition of fair value step-up in the Bioquell inventory and severance related to the closure of a facility. We also incurred $0.2 million ($0.1 million after tax) or less than $0.01 per diluted share, of interest expense in the first nine months of 2019.

### Disposal and impairment charges

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statement of Income include $45.9 million ($45.0 million after tax) or $0.15 per diluted share in the first nine months of 2020. During the second quarter of 2020, we recorded a $28.6 million ($28.6 million after tax) or $0.10 per diluted share impairment for a minority equity method investment due to the COVID-19 impact on the economic environment and the liquidity of the minority equity method investment. In addition, we recorded charges of $17.3 million ($16.3 million after tax) or $0.06 per diluted share related to the disposal of Holchem Group Limited (“Holchem”) for the loss on sale and related transaction fees during the first six months of 2020. Further information related to the disposal is included in Note 3.

### Other

During the third quarter and first nine months of 2020, we recorded charges of $4.1 million and $30.6 million, respectively, to protect the pay for certain employees directly impacted by the COVID-19 pandemic. In addition, we received subsidies and government assistance, which was recorded as a special (gain) of ($5.3) million and ($14.7) million during the third quarter and first nine months of 2020, respectively. COVID-19 pandemic charges are recorded in product and equipment sales, service and lease sales, and special (gains) and charges on the Consolidated Statement of Income. Total after tax net charges (gains) related to COVID-19 pandemic were ($0.9) million or less than $0.01 per diluted share, and $12.3 million or $0.04 per diluted share during the third quarter and first nine months of 2020, respectively.

During the third quarter and first nine months of 2020, we recorded special charges of $5.2 million ($3.5 million after tax) or $0.01 per diluted share and $26.2 million ($17.8 million after tax) or $0.06 per diluted share, respectively, recorded in product and equipment cost of sales on the Consolidated Statement of Income primarily related to a Healthcare product recall in Europe.

During the third quarter of 2020, we recorded special charges of $83.1 million ($64.0 million after tax) or $0.22 per diluted share in interest expense on the Consolidated Statement of Income primarily related to debt refinancing charges.

Other special charges of $8.4 million ($7.2 million after tax) or $0.02 per diluted share and $30.3 million ($23.7 million after tax) or $0.08 per diluted share recorded in the third quarter and first nine months of 2020, respectively, relate primarily to a specific legal reserve and related legal charges which are recorded in special (gains) and charges on the Consolidated Statement of Income.

During the third quarter and first nine months of 2019, we recorded other special charges of $3.6 million ($2.7 million after tax) or less than $0.01 per diluted share and $13.7 million ($10.3 million after tax) or $0.04 per diluted share, respectively, which primarily related to legal charges.

### Operating Income and Operating Income Margin

| ​ ​ ​ ​ (millions) | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2020 2019 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2020 2019 ​ | ​ ​ ​ ​ Change |
| --- | --- | --- | --- | --- | --- | --- |
| Reported GAAP operating income | ​ | **​** **$411.4** **​** ​ ​ $549.0 ​ | **(25)%** | ​ | **​** **$979.6** **​** ​ ​ $1,327.0 ​ | **(26)%** |
| Special (gains) and charges | ​ | **44.5** **​** ​ 36.3 ​ | ​ ​ | ​ | **165.9** **​** ​ 111.6 ​ | ​ ​ |
| Non-GAAP adjusted operating income | ​ | **455.9** **​** ​ 585.3 ​ | **(22)%** | ​ | **1,145.5** **​** ​ 1,438.6 ​ | **(20)%** |
| Effect of foreign currency translation | ​ | **5.8** **​** ​ 2.9 ​ | ​ ​ | ​ | **22.7** **​** ​ 3.9 ​ | ​ ​ |
| Non-GAAP adjusted fixed currency operating income | ​ | **​** **$461.7** **​** ​ ​ $588.2 ​ | **(22)%** | ​ | **​** **$1,168.2** **​** ​ ​ $1,442.5 ​ | **(19)%** |
| ​ | ​ | ​ **​** **​** ​ ​ ​ ​ | ​ ​ | ​ | ​ **​** **​** ​ ​ ​ ​ | ​ ​ |
| ​ | ​ | Third Quarter Ended | ​ ​ | ​ | Nine Months Ended | ​ ​ |
| ​ | ​ | September 30 | ​ ​ | ​ | September 30 | ​ ​ |
| (percent) | ​ | **2020** ​ 2019 | ​ ​ | ​ | **2020** ​ 2019 | ​ ​ |
| Reported GAAP operating income margin | ​ | **​** **13.6%** ​ ​ 17.0% | ​ ​ | ​ | **​** **11.2%** ​ ​ 14.2% | ​ ​ |
| Non-GAAP adjusted operating income margin | ​ | **​** **15.1%** ​ ​ 18.2% | ​ ​ | ​ | **​** **13.1%** ​ ​ 15.4% | ​ ​ |
| Non-GAAP adjusted fixed currency operating income margin | ​ | **​** **15.2%** ​ ​ 18.2% | ​ ​ | ​ | **​** **13.2%** ​ ​ 15.5% | ​ ​ |

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by net sales.

Our reported operating income decreased 25% and 26% in the third quarter and first nine months of 2020, respectively, versus the comparable periods of 2019. Our reported operating income for 2020 and 2019 was impacted by special (gains) and charges; excluding the impact of special (gains) and charges from 2020 and 2019 reported results, our adjusted operating income decreased 22% and 20% in the third quarter and first nine months of 2020, respectively.

As shown in the previous table, foreign currency had a 0% and 1% impact on adjusted operating income growth for the third quarter and first nine months of 2020, respectively. Foreign currency had a 1% and 2% impact on adjusted operating income growth for the third quarter and first nine months of 2019, respectively.

### Other (Income) Expense

Other income was $15.1 million and $20.8 million in the third quarter of 2020 and 2019, respectively. Other income was $45.6 million and $62.9 million in the first nine months of 2020 and 2019, respectively. Other income decreased due to amortization of prior year losses driven by the impact of lower discount rates on liabilities.

### Interest Expense, Net

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ ​ ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ ​ ​ | ​ ​ ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: |
| Reported GAAP interest expense, net | ​ | **​** | **$134.8** | **​** | ​ | ​ | $46.1 | ​ | **192%** | ​ | **​** | **$241.8** | **​** | ​ | ​ | $144.6 | ​ | **67%** |
| Special (gains) and charges | ​ | **​** | **83.1** | **​** | ​ |  | - | ​ | ​ ​ | ​ | **​** | **83.8** | **​** | ​ |  | 0.2 | ​ | ​ ​ |
| Non-GAAP adjusted interest expense, net | ​ | **​** | **$51.7** | **​** | ​ | ​ | $46.1 | ​ | **12%** | ​ | **​** | **$158.0** | **​** | ​ | ​ | $144.4 | ​ | **9%** |

Reported net interest expense was $134.8 million and $46.1 million in the third quarter of 2020 and 2019, respectively. Reported net interest expense was $241.8 million and $144.6 million in the first nine months of 2020 and 2019, respectively. In the third quarter of 2020, we incurred $83.1 million of expense associated with debt refinancing. The increase in adjusted net interest expense when comparing 2020 against 2019 was driven primarily by higher outstanding debt.

### Provision for Income Taxes

The following table provides a summary of our tax rate:

| ​ ​ ​ (percent) ​ | ​ ​ ​ ​ | ​ ​ Third Quarter Ended September 30 2020 ​ ​ | ​ ​ ​ | ​ ​ 2019 ​ ​ | ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30 2020 ​ ​ | ​ ​ ​ | ​ ​ 2019 ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Reported GAAP tax rate | **​** | **14.5%** | **​** | 15.9% | **​** | 13.2% | **​** | 16.2% |
| Tax rate impact of: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Special (gains) and charges |  | **2.6** **​** | **​** | 1.2 ​ | **​** | **1.6** **​** | **​** | 1.0 |
| Discrete tax items |  | **2.9** **​** | **​** | 2.5 ​ | **​** | **5.5** **​** | **​** | 2.9 |
| Non-GAAP adjusted tax rate |  | **20.0%** | **​** | 19.6% |  | **20.3%** | **​** | 20.1% |

Our reported tax rate was 14.5% and 15.9% for the third quarter of 2020 and 2019, respectively, and 13.2% and 16.2% for the first nine months of 2020 and 2019, respectively. The change in our tax rate for the third quarter and first nine months of 2020 versus the comparable period of 2019 was driven primarily by discrete tax items and special (gains) and charges. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future as amounts included in special (gains) and charges are derived from tax jurisdictions with rates that vary from our effective tax rate, and discrete tax items are not necessarily consistent across periods. Further information related to special (gains) and charges is included in Note 2. Our tax rate is based on our interpretation of existing tax rules; potential future guidance including regulations not yet issued could impact the future tax rate.

We recognized total net tax benefits related to discrete tax items of $12.4 million and $56.8 million in the third quarter and first nine months of 2020, respectively. Share-based compensation excess tax benefit contributed $3.4 million and $49.0 million in the third quarter and first nine months of 2020, respectively. Additionally, we recognized a net tax benefit of $6.9 million and $2.4 million primarily related to the release of a valuation allowance, the filing of prior year foreign tax returns and other income tax adjustments in the third quarter and first nine months of 2020, respectively. The remaining discrete net tax benefit of $2.1 million and $5.4 million was due to the net release of reserves for uncertain tax positions during the third quarter and the first nine months of 2020, respectively.

We recognized total net tax benefits related to discrete tax items of $13.6 million and $39.8 million in the third quarter and first nine months of 2019, respectively. Share-based compensation excess tax benefit contributed $7.9 million and $39.4 million in the third quarter and first nine months of 2019, respectively. We also recognized a net tax benefit of $4.3 million and $3.2 million in the third quarter and first nine months of 2019, respectively, due to finalization of certain estimates due to the 2018 U.S. federal tax return for the one-time transition tax imposed by the Tax Cuts and Jobs Act (the “Act”). Additionally, we recognized a net tax benefit of $1.1 million related to foreign audit settlements and related reserve releases during the quarter. The remaining net discrete benefit (expense) was primarily due to changes in estimates in non-U.S. jurisdictions and from the 2018 U.S. federal tax return.

### Net Income from Continuing Operations Attributable to Ecolab

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Reported GAAP net income from continuing operations attributable to Ecolab | **​** | **​** | **$246.2** | **​** | ​ | ​ | $435.9 | **​** | **(44)%** | **​** | **​** | **$667.1** | **​** | ​ | ​ | $1,030.9 | **​** | **(35)%** |
| Adjustments: | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ |
| Special (gains) and charges, after tax | ​ |  | **98.5** | **​** | ​ | ​ | 23.8 | ​ | **​** ​ | ​ | **​** | **200.3** | **​** | ​ | ​ | 80.9 | ​ | **​** ​ |
| Discrete tax net expense (benefit) | ​ |  | **(12.4)** | **​** | ​ | ​ | (13.6) | ​ | **​** ​ | ​ | **​** | **(56.8)** | **​** | ​ | ​ | (39.8) | ​ | **​** ​ |
| Non-GAAP adjusted net income from continuing operations attributable to Ecolab | ​ | **​** | **$332.3** | **​** | ​ | ​ | $446.1 | ​ | **(26)%** | ​ | **​** | **$810.6** | **​** | ​ | ​ | $1,072.0 | ​ | **(24)%** |

### Diluted EPS from Continuing Operations

| ​ ​ ​ (dollars) | ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Reported GAAP diluted EPS from continuing operations | **​** | **​** | **$0.85** | **​** | ​ | ​ | $ 1.49 | **​** | **(43)%** | **​** | **​** | **$2.29** | **​** | ​ | ​ | $ 3.52 | **​** | **(35)%** |
| Adjustments: | ​ | ​ | **​** | ​ | ​ | ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ ​ |
| Special (gains) and charges | **​** |  | **0.34** | **​** | ​ | ​ | 0.08 | ​ | ​ ​ | **​** | **​** | **0.69** | **​** | ​ | ​ | 0.28 | ​ | ​ ​ |
| Discrete tax net expense (benefit) | ​ |  | **(0.04)** | **​** | ​ | ​ | (0.05) | ​ | ​ ​ | ​ | **​** | **(0.20)** | **​** | ​ | ​ | (0.14) | ​ | ​ ​ |
| Non-GAAP adjusted diluted EPS from continuing operations | ​ | **​** | **$1.15** | **​** | ​ | ​ | $ 1.52 | ​ | **(24)%** | ​ | **​** | **$2.79** | **​** | ​ | ​ | $ 3.66 | ​ | **(24)%** |

Per share amounts in the above tables do not necessary sum due to rounding.

Currency translation had an unfavorable impact of approximately $0.01 and $0.06 per share on diluted EPS for the third quarter and first nine months of 2020, respectively, when compared to the comparable periods of 2019.

### DISCONTINUED OPERATIONS

The ChampionX business met the criteria to be reported as discontinued operations and the historical results of ChampionX, including the results of operations, are reported as discontinued operations for all periods presented. The net loss from discontinued operations, net of tax was $2,172.5 million in the first nine months of 2020. Net income from discontinued operations, net of tax was $28.3 million and $98.4 million in the third quarter and first nine months of 2019, respectively.

During the second quarter of 2020, in connection with the ChampionX Separation, Ecolab received cash of $527 million and $1,051 million of non-cash consideration of approximately 5.0 million shares of Ecolab common stock for the ChampionX net assets, including cumulative translation adjustment, of $3,717, resulting in a loss.

Special (gains) and charges of $2,222.7 million in the first nine months of 2020 primarily relate to the loss on separation, transaction fees, and other professional fees incurred to support the Transaction. Special (gains) and charges of $35.5 million and $61.8 million in the third quarter and first nine months of 2019, respectively, primarily relate to restructuring charges and transaction fees and other professional fees incurred to support the Transaction.

### SEGMENT PERFORMANCE

The non-U.S. dollar functional international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates used by management for 2020. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2 of our Annual Report on Form 10-K for the year ended December 31, 2019. Additional information about our reportable segments is included in Note 16.

Fixed currency net sales and operating income for the third quarter and first nine months of 2020 and 2019 for our reportable segments are shown in the following tables.

| ​ Net Sales ​ (millions) | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2020 2019 ​ ​ Change | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2020 2019 ​ ​ Change |
| --- | --- | --- | --- | --- |
| Global Industrial | **​** | **​** **$1,491.1** **​** ​ $1,517.1 ​ **(2)%** | **​** | **​** **$4,410.3** **​** ​ $4,414.8 ​ **(0)%** |
| Global Institutional & Specialty |  | **​** **901.3** **​** ​ 1,150.6 ​ ​ **(22)** ​ |  | **​** **2,695.8** **​** ​ 3,283.3 ​ ​ **(18)** ​ |
| Global Healthcare & Life Sciences | **​** | **​** **320.9** **​** ​ ​ 243.9 ​ ​ **32** ​ | **​** | **​** **875.0** **​** ​ ​ 723.7 ​ ​ **21** ​ |
| Other | **​** | **​** **285.7** **​** ​ ​ 323.1 ​ ​ **(12)** ​ | **​** | **​** **810.4** **​** ​ ​ 904.0 ​ ​ **(10)** ​ |
| Corporate |  | **​** **48.2** **​** ​ - ​ ​ **100** ​ |  | **​** **60.5** **​** ​ - ​ ​ **100** ​ |
| Subtotal at fixed currency |  | **​** **3,047.2** **​** ​ 3,234.7 ​ ​ **(6)** ​ |  | **​** **8,852.0** **​** ​ 9,325.8 ​ ​ **(5)** ​ |
| Effect of foreign currency translation |  | **​** **(28.6)** **​** ​ (10.7) ​ ​ **​** ​ |  | **​** **(127.1)** **​** ​ (8.0) ​ ​ **​** ​ |
| Consolidated reported GAAP net sales |  | **​** **$3,018.6** **​** ​ ​ $3,224.0 ​ ​ **(6)%** |  | **​** **$8,724.9** **​** ​ ​ $9,317.8 ​ ​ **(6)%** |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | Third Quarter Ended | ​ | Nine Months Ended |
| ​ | **​** | September 30 | ​ | September 30 |
| (millions) | ​ | **2020** 2019 ​ ​ **Change** | ​ | **2020** 2019 ​ ​ **Change** |
| Global Industrial |  | **$297.8** **​** ​ $249.8 **​** **19%** | ​ | **$787.4** **​** ​ $632.1 **​** **25%** |
| Global Institutional & Specialty |  | **​** **82.6** **​** ​ 280.9 **​** **(71)** ​ | ​ | **​** **228.0** **​** ​ 690.1 **​** **(67)** ​ |
| Global Healthcare & Life Sciences | **​** | **​** **66.0** **​** ​ ​ 36.3 **​** **​** **82** ​ | ​ | **​** **154.5** **​** ​ ​ 92.3 **​** **​** **67** ​ |
| Other |  | **​** **45.2** **​** ​ 51.4 **​** **(12)** ​ | ​ | **​** **88.1** **​** ​ 119.0 **​** **(26)** ​ |
| Corporate |  | **​** **(74.4)** **​** ​ (66.5) ​ ​ ​ ​ | ​ | **​** **(255.7)** **​** ​ (202.6) ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **​** **417.2** **​** ​ 551.9 **​** **(24)** ​ | ​ | **​** **1,002.3** **​** ​ 1,330.9 **​** **(25)** ​ |
| Effect of foreign currency translation |  | **​** **(5.8)** **​** ​ (2.9) ​ ​ **​** ​ | ​ | **​** **(22.7)** **​** ​ (3.9) ​ ​ **​** ​ |
| Consolidated reported GAAP operating income |  | **$411.4** **​** ​ ​ $549.0 **​** **(25)%** | ​ | **$979.6** **​** ​ ​ $1,327.0 **​** **(26)%** |

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

| ​ ​ ​ Net Sales (millions) | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2020 ​ 2019 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| --- | --- | ---: |
| Global Industrial | **​** | **$1,491.1** **​** **$(36.2)** **​** **$1,454.9** ​ $1,517.1 ​ $(16.7) ​ $1,500.4 |
| Global Institutional & Specialty |  | **901.3** **​** **(4.3)** **​** **897.0** ​ 1,150.6 ​ - ​ 1,150.6 |
| Global Healthcare & Life Sciences | **​** | **320.9** **​** **(6.5)** **​** **314.4** ​ 243.9 ​ (0.5) ​ 243.4 |
| Other |  | **285.7** **​** **-** **​** **285.7** ​ 323.1 ​ - ​ 323.1 |
| Corporate |  | **48.2** **​** **(48.2)** **​** **-** ​ - ​ - ​ - |
| Subtotal at fixed currency |  | **3,047.2** **​** **(95.2)** **​** **2,952.0** ​ 3,234.7 ​ (17.2) ​ 3,217.5 |
| Effect of foreign currency translation |  | **(28.6)** **​** ​ **​** ​ ​ (10.7) ​ ​ ​ ​ |
| Total reported net sales |  | **$3,018.6** **​** ​ **​** ​ ​ $3,224.0 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2020** ​ 2019 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$297.8** **​** **$(4.4)** **​** **$293.4** ​ $249.8 ​ $(1.1) ​ $248.7 |
| Global Institutional & Specialty |  | **82.6** **​** **(0.8)** **​** **81.8** ​ 280.9 ​ - ​ 280.9 |
| Global Healthcare & Life Sciences | **​** | **66.0** **​** **(0.2)** **​** **65.8** ​ 36.3 ​ (0.1) ​ 36.2 |
| Other |  | **45.2** **​** **-** **​** **45.2** ​ 51.4 ​ - ​ 51.4 |
| Corporate |  | **(29.9)** **​** **-** **​** **(29.9)** ​ (30.2) ​ - ​ (30.2) |
| Non-GAAP adjusted fixed currency operating income |  | **461.7** **​** **(5.4)** **​** **456.3** ​ 588.2 ​ (1.2) ​ 587.0 |
| Special (gains) and charges |  | **44.5** **​** **​** **​** **​** ​ 36.3 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **417.2** **​** **​** **​** **​** ​ 551.9 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(5.8)** **​** **​** **​** **​** ​ (2.9) ​ ​ ​ ​ |
| Total reported operating income |  | **$411.4** **​** **​** **​** **​** ​ $549.0 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| ​ | **​** | Nine Months Ended |
| **​** | **​** | September 30 |
| **Net Sales** | **​** | **2020** ​ 2019 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$4,410.3** **​** **(45.0)** **​** **$4,365.3** ​ $4,414.8 ​ (17.4) ​ $4,397.4 |
| Global Institutional & Specialty |  | **2,695.8** **​** **(31.3)** **​** **2,664.5** ​ 3,283.3 ​ - ​ 3,283.3 |
| Global Healthcare & Life Sciences | **​** | **875.0** **​** **(21.9)** **​** **853.1** ​ 723.7 ​ (0.9) ​ 722.8 |
| Other | **​** | **810.4** **​** **(1.0)** **​** **809.4** ​ 904.0 ​ (0.1) ​ 903.9 |
| Corporate |  | **60.5** **​** **(60.5)** **​** **-** ​ - ​ - ​ - |
| Subtotal at fixed currency |  | **8,852.0** **​** **(159.7)** **​** **8,692.3** ​ 9,325.8 ​ (18.4) ​ 9,307.4 |
| Effect of foreign currency translation |  | **(127.1)** **​** ​ **​** ​ ​ (8.0) ​ ​ ​ ​ |
| Total reported net sales |  | **$8,724.9** **​** ​ **​** ​ ​ $9,317.8 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2020** ​ 2019 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$787.4** **​** **(5.4)** **​** **$782.0** ​ $632.1 ​ (1.0) ​ $631.1 |
| Global Institutional & Specialty |  | **228.0** **​** **(2.2)** **​** **225.8** ​ 690.1 ​ - ​ 690.1 |
| Global Healthcare & Life Sciences |  | **154.5** **​** **0.4** **​** **154.9** ​ 92.3 ​ (0.1) ​ 92.2 |
| Other | **​** | **88.1** **​** **(0.2)** **​** **87.9** ​ 119.0 ​ (0.1) ​ 118.9 |
| Corporate |  | **(89.8)** **​** **-** **​** **(89.8)** ​ (91.0) ​ - ​ (91.0) |
| Non-GAAP adjusted fixed currency operating income |  | **1,168.2** **​** **(7.4)** **​** **1,160.8** ​ 1,442.5 ​ (1.2) ​ 1,441.3 |
| Special (gains) and charges |  | **165.9** **​** **​** **​** **​** ​ 111.6 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **1,002.3** **​** **​** **​** **​** ​ 1,330.9 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(22.7)** **​** **​** **​** **​** ​ (3.9) ​ ​ ​ ​ |
| Total reported operating income |  | **$979.6** **​** **​** **​** **​** ​ $1,327.0 ​ ​ ​ ​ |

Unless otherwise noted, the following segment performance commentary compares the third quarter and first nine months of 2020 against the third quarter and first nine months of 2019.

### Global Industrial

| ​ ​ ​ ​ | ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$1,491.1** ​ | ​ | ​ | $1,517.1 ​ | **​** | **​** | **$4,410.3** ​ | ​ | ​ | $4,414.8 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **1,470.2** ​ | ​ | ​ | 1,512.6 ​ | **​** | **​** | **4,329.4** ​ | ​ | ​ | 4,414.8 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **(4)%** | **​** |  | ​ ​ | **​** |  | **(2)%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(3)%** | **​** | ​ | ​ ​ | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **(2)%** | **​** |  | ​ ​ | **​** |  | **0%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | **​** | **​** | **(2)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **(3)%** | **​** |  | ​ ​ | **​** |  | **(2)%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$297.8** ​ | ​ | ​ | $249.8 ​ | **​** | **​** | **$787.4** ​ | ​ | ​ | $632.1 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **293.4** ​ | ​ | ​ | 248.1 ​ | **​** | **​** | **770.5** ​ | ​ | ​ | 631.0 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **19%** | **​** | ​ | ​ ​ | **​** | **​** | **25%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **20.0%** | **​** |  | 16.5% | **​** |  | **17.9%** | **​** |  | 14.3% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **18%** | **​** |  | ​ ​ | **​** |  | **24%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **20.2%** | **​** |  | 16.6% | **​** |  | **17.9%** | **​** |  | 14.4% | ​ |
| Public currency operating income change | ​ | ​ | **18%** | ​ | ​ | ​ ​ | ​ | ​ | **22%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Industrial decreased in the third quarter and first nine months of 2020, as lower volume more than offset pricing. In the third quarter and first nine months, declines in North America more than offset gains in other regions.

At an operating segment level, ***Water*** fixed currency sales decreased 2% in both the third quarter and first nine months of 2020. Light industry water treatment sales showed modest growth as improving commercial building water treatment demand, along with additional water hygiene programs as they reopen and new business gains more than offset the impact of reduced transportation industry production versus last year. Heavy industry sales declined moderately as a slower recovery in primary metals and chemical production continued to impact our sales to those industries. Mining declined modestly as gains in precious metals and fertilizers were more than offset by weak coal and alumina markets. ***Food & Beverage*** fixed currency sales increased 5% (0% acquisition adjusted) and 5% (3% acquisition adjusted) in the third quarter and first nine months of 2020, respectively, led by good growth in the food business reflecting steady end market trends. Beverage and brewing was flat and protein declined reflecting unfavorable COVID-related effects on consumption. ***Downstream*** fixed currency sales decreased 11% in the third quarter of 2020 and 5% in the first nine months of 2020 as steady petrochemical demand was more than offset by the negative impact of lower global transportation fuel demand on refineries and the use of lighter crudes. ***Paper*** fixed currency sales decreased 4% in the third quarter of 2020 and were flat in the first nine months of 2020, as slower industrial packaging trends and declines in graphic paper more than offset moderate gains in tissue.

### Operating Income

Fixed currency operating income and fixed currency operating income margins increased for Global Industrial in the third quarter and first nine months of 2020.

Acquisition adjusted fixed currency operating income margins increased 3.6 and 3.5 percentage points during the third quarter and first nine months of 2020, respectively, and were positively impacted approximately 4.6 and 4.0 percentage points in the third quarter and first nine months of 2020, respectively, by favorable pricing, lower discretionary spending and cost savings initiatives, and lower delivered product costs, which more than offset the 1.2 and 0.7 percentage point negative impact of reduced operating leverage and lower volume during the third quarter and first nine months of 2020, respectively.

### Global Institutional & Specialty

| ​ ​ ​ ​ | ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$901.3** ​ | ​ | ​ | $1,150.6 ​ | **​** | **​** | **$2,695.8** ​ | ​ | ​ | $3,283.3 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **896.3** ​ | ​ | ​ | 1,148.1 ​ | **​** | **​** | **2,671.4** ​ | ​ | ​ | 3,279.3 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **(23)%** | **​** |  | ​ ​ | **​** |  | **(20)%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(22)%** | **​** | ​ | ​ ​ | **​** | **​** | **(19)%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **0%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **(22)%** | **​** |  | ​ ​ | **​** |  | **(18)%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **0%** | **​** | ​ | ​ ​ | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **(22)%** | **​** |  | ​ ​ | **​** |  | **(19)%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$82.6** ​ | ​ | ​ | $280.9 ​ | **​** | **​** | **$228.0** ​ | ​ | ​ | $690.1 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **82.0** ​ | ​ | ​ | 280.4 ​ | **​** | **​** | **225.9** ​ | ​ | ​ | 688.6 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **(71)%** | **​** | ​ | ​ ​ | **​** | **​** | **(67)%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **9.2%** | **​** |  | 24.4% | **​** |  | **8.5%** | **​** |  | 21.0% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(71)%** | **​** |  | ​ ​ | **​** |  | **(67)%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **9.1%** | **​** |  | 24.4% | **​** |  | **8.5%** | **​** |  | 21.0% | ​ |
| Public currency operating income change | ​ | ​ | **(71)%** | ​ | ​ | ​ ​ | ​ | ​ | **(67)%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Institutional & Specialty decreased in the third quarter and first nine months of 2020, driven by a decline in the Institutional business. At a regional level, the third quarter and first nine months of 2020 fixed currency sales decreased in all major regions.

At an operating segment level, ***Institutional*** fixed currency sales decreased 28% and 27% in the third quarter and first nine months of 2020, respectively, reflecting strong hand and surface hygiene sales that were more than offset by mandated reductions for in-unit dining and domestic and international travel that significantly impacted foot traffic at full-service restaurants, occupancy rates at hotels and a reduction of customer visits to other entertainment facilities through the quarter. All geographic regions declined. ***Specialty*** fixed currency sales increased 1% (0% acquisition adjusted) and 12% (7% acquisition adjusted) in the third quarter and first nine months of 2020, respectively, as good food retail sales growth was offset by moderately lower quickservice sales for the quarter. Food retail sales benefited from continued expanded cleaning protocols and frequency in the grocery stores in response to COVID-19, new customer additions and product and program introductions. Global quickservice sales declined moderately as strong hand and surface sanitizer sales offset by COVID-19 related impacts on restaurant volumes.

### Operating Income

Fixed currency operating income and fixed currency operating income margins decreased for our Global Institutional & Specialty segment in the third quarter and first nine months of 2020.

Acquisition adjusted fixed currency operating income margins decreased 15.3 and 12.5 percentage points during the third quarter and first nine months of 2020, respectively. Margins were negatively impacted approximately 15.8 and 13.0 percentage points in the third quarter and first nine months of 2020, respectively, from volume declines, reduced operating leverage and unfavorable mix, which more than offset the 1.1 and 1.2 percentage point positive impact cost savings initiatives and lower discretionary spending during the third quarter and first nine months of 2020, respectively.

### Global Healthcare & Life Sciences

| ​ ​ ​ ​ | ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$320.9** ​ | ​ | ​ | $243.9 ​ | ​ | **​** | **$875.0** ​ | ​ | ​ | $723.7 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **321.5** ​ | ​ | ​ | 241.7 ​ | ​ | **​** | **863.8** ​ | ​ | ​ | 721.1 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **29%** | **​** |  | ​ ​ | ​ |  | **17%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **1%** | **​** |  | ​ ​ | ​ |  | **1%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **29%** | **​** | ​ | ​ ​ | ​ | **​** | **18%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **2%** | **​** |  | ​ ​ | ​ |  | **3%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **32%** | **​** |  | ​ ​ | ​ |  | **21%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **1%** | **​** | ​ | ​ ​ | ​ | **​** | **(1)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **33%** | **​** |  | ​ ​ | ​ |  | **20%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$66.0** ​ | ​ | ​ | $36.3 ​ | ​ | **​** | **$154.5** ​ | ​ | ​ | $92.3 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **65.7** ​ | ​ | ​ | 35.7 ​ | ​ | **​** | **151.2** ​ | ​ | ​ | 91.5 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **82%** | **​** | ​ | ​ ​ | ​ | **​** | **67%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **20.6%** | **​** |  | 14.9% | ​ |  | **17.7%** | **​** |  | 12.8% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **82%** | **​** |  | ​ ​ | ​ |  | **68%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **20.9%** | **​** |  | 14.9% | ​ |  | **18.2%** | **​** |  | 12.8% | ​ |
| Public currency operating income change | ​ | ​ | **84%** | ​ | ​ | ​ ​ | ​ | ​ | **65%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for the Global Healthcare & Life Sciences increased in the third quarter and first nine months of 2020, driven by volume gains. At a regional level, the third quarter and first nine months of 2020 fixed currency sales increased in all regions.

At an operating segment level, ***Healthcare*** fixed currency sales increased 29% (25% acquisition adjusted) and 17% (14% acquisition adjusted) in the third quarter and first nine months of 2020, respectively, as strong COVID-19 related hand and surface disinfection sales growth more than offset the unfavorable effects of delayed elective surgical procedures. ***Life Sciences*** fixed currency sales increased 47% (48% acquisition adjusted) and 42% (40% acquisition adjusted) in the third quarter and first nine months of 2020, respectively, driven by significant demand for our Bioquell biodecontamination systems due to COVID-19 concerns and increased cleaning standards, which bolstered our ongoing business wins and pricing.

### Operating Income

Fixed currency operating income and fixed currency operating income margins for our Global Healthcare & Life Sciences segment increased in the third quarter and first nine months of 2020.

Acquisition adjusted fixed currency operating income margins increased 6.0 and 5.4 percentage points during the third quarter and first nine months of 2020, respectively. Strong volume gains, favorable mix, improved pricing and cost savings initiatives impacted margins by approximately 7.4 and 6.0 percentage points during the third quarter and first nine months of 2020, respectively, which more than offset higher delivered product costs which negatively impacted margins by 1.7 and 0.9 percentage points during the third quarter and first nine months of 2020, respectively.

### Other

| ​ ​ ​ ​ | ​ ​ ​ | ​ Third Quarter Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$285.7** ​ | ​ | ​ | $323.1 ​ | **​** | **​** | **$810.4** ​ | ​ | ​ | $904.0 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **283.7** ​ | ​ | ​ | 321.6 ​ | **​** | **​** | **801.1** ​ | ​ | ​ | 902.6 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **(13)%** | **​** |  | ​ ​ | **​** |  | **(12)%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(12)%** | **​** | ​ | ​ ​ | **​** | **​** | **(10)%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **0%** | **​** |  | ​ ​ | **​** |  | **0%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **(12)%** | **​** |  | ​ ​ | **​** |  | **(10)%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **0%** | **​** | ​ | ​ ​ | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **(12)%** | **​** |  | ​ ​ | **​** |  | **(11)%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$45.2** ​ | ​ | ​ | $51.4 ​ | **​** | **​** | **$88.1** ​ | ​ | ​ | $119.0 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **44.7** ​ | ​ | ​ | 51.2 ​ | **​** | **​** | **87.1** ​ | ​ | ​ | 118.7 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **(12)%** | **​** | ​ | ​ ​ | **​** | **​** | **(26)%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **15.8%** | **​** |  | 15.9% | **​** |  | **10.9%** | **​** |  | 13.2% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(12)%** | **​** |  | ​ ​ | **​** |  | **(26)%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **15.8%** | **​** |  | 15.9% | **​** |  | **10.9%** | **​** |  | 13.2% | ​ |
| Public currency operating income change | ​ | ​ | **(13)%** | ​ | ​ | ​ ​ | ​ | ​ | **(27)%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Other decreased in the third quarter and first nine months of 2020 due to the impact of COVID-19 on partial and full customer closures along with limited vendor access. At a regional level, the decline in third quarter and first nine months of 2020 sales results mostly impacted North America and Europe.

At an operating segment level, ***Pest Elimination*** fixed currency sales decreased 2% and 3% (4% acquisition adjusted) in the third quarter and first nine months of 2020, respectively. Sales growth in food and beverage plants, grocery stores and healthcare facilities was offset by the impact of lower restaurant and hospitality volumes. ***Textile Care*** fixed currency sales decreased 32% and 27% in the third quarter and first nine months of 2020, respectively. ***Colloidal Technologies Group*** fixed currency sales decreased 30% and 18% in the third quarter and first nine months of 2020, respectively.

### Operating Income

Acquisition adjusted fixed currency operating income margins for Other decreased 0.1 and 2.3 percentage points during the third quarter and first nine months of 2020, respectively. Lower volume and reduced operating leverage negatively impacted margins by approximately 3.6 and 4.5 percentage points for the third quarter and first nine months of 2020, respectively. These margin declines were partially offset by lower discretionary spending, improved pricing and cost savings initiatives which positively impacted margins by approximately 3.4 and 2.7 percentage points for the third quarter and first nine months of 2020, respectively.

### Corporate

Consistent with our internal management reporting, Corporate amounts in the table on page 43 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 4, intangible asset amortization specifically from the Nalco merger and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 39.

### FINANCIAL POSITION, CASH FLOWS AND LIQUIDITY

### Financial Position

Total assets were $18.1 billion as of September 30, 2020 compared to total assets of $20.9 billion as of December 31, 2019. The decrease in total assets reflects the separation of ChampionX.

Total liabilities were $12.0 billion as of September 30, 2020 compared to total liabilities of $12.1 billion as of December 31, 2019. Total debt was $6.9 billion as of September 30, 2020 and $6.4 billion as of December 31, 2019. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”) is shown in the following table. EBITDA is a non-GAAP measures discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

The inputs to EBITDA reflect the trailing twelve months of activity for the period presented.

| ​ ​ (ratio) | ​ ​ | ​ 2020 ​ | ​ ​ | ​ ​ | ​ ​ | ​ 2019 ​ | ​ ​ | ​ ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Net debt to EBITDA |  | **​** | **2.5** | **​** |  | ​ | 2.3 | ​ |  |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** |
| (millions) |  | **​** | **​** | **​** | ​ | ​ | ​ | ​ |  |
| Total debt | **​** | **​** | **$6,915.0** | **​** | ​ | ​ | $6,353.6 | ​ | **​** |
| Cash | **​** |  | **1,034.7** | **​** | ​ | ​ | 118.8 | ​ | **​** |
| Net debt | **​** | **​** | **$5,880.3** | **​** | ​ | ​ | $6,234.8 | ​ | **​** |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** |
| Net income including noncontrolling interest | ​ | **​** | **$1,079.5** | **​** | ​ | ​ | $1,442.9 | ​ | ​ |
| Provision for income taxes | **​** |  | **190.1** | **​** | ​ | ​ | 288.6 | ​ | **​** |
| Interest expense, net | **​** |  | **287.9** | **​** | ​ | ​ | 190.8 | ​ | **​** |
| Depreciation | **​** |  | **588.3** | **​** | ​ | ​ | 569.1 | ​ | **​** |
| Amortization | **​** |  | **213.1** | **​** | ​ | ​ | 206.2 | ​ | **​** |
| EBITDA | **​** |  | **$2,358.9** | **​** | ​ | ​ | $2,697.6 | ​ | **​** |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** |

### Cash Flows

### Operating Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Cash provided by operating activities | ​ | **​** | **$1,092.0** | ​ | ​ | ​ | $1,299.0 | ​ | ​ | **​** | **$(207.0)** | **​** | **​** |

We continue to generate cash flow from operations, amidst the COVID-19 pandemic, allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases. Cash provided by operating activities decreased $207 million in the first nine months of 2020 compared to the first nine months of 2019, driven primarily by a $363 million reduction in net income from continuing operations including noncontrolling interest and $35 million higher net cash payments for restructuring, partially offset by $114 million due to lower pension and post retirement plan contributions and $98 million due to favorable fluctuations in accounts receivable, inventories and accounts payable (“working capital”). The cash flow impact from working capital accounts was driven by lower sales volume, partially offset by lower accounts receivable and inventory turnover.

### Investing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Cash used for investing activities | ​ | **​** | **$(795.9)** | ​ | ​ | ​ | $(881.1) | ​ | ​ | **​** | **$85.2** | **​** | **​** |

49

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as capital investments in the business.

Total cash paid for acquisitions, net of cash acquired along with net cash received from dispositions, during the first nine months of 2020 and 2019, was $432 million and $380 million, respectively. Our acquisitions and divestitures are discussed further in Note 3. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

We continue to make capital investments in the business, including merchandising, customer equipment and manufacturing facilities. Total capital expenditures were $362 million and $504 million in the first nine months of 2020 and 2019, respectively.

### Financing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Cash provided by (used for) financing activities | ​ | **​** | **$30.3** | ​ | ​ | ​ | $(844.6) | ​ | ​ | **​** | **$874.9** | **​** | **​** |

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $1,850 million par value and received $1,856 million in proceeds of long-term debt in the first nine months of 2020. We repaid $1,570 million and $401 million of long-term debt in the first nine months of 2020 and 2019, respectively. The proceeds received from the debt issuances were used for repayment of outstanding debt, repayment of commercial paper and general corporate purposes. In addition, we had net issuances of commercial paper of $166 million and $150 million in the first nine months of 2020 and 2019, respectively.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans and stock issued in acquisitions, to manage our capital structure and to efficiently return capital to shareholders. We repurchased a total of $125 million and $349 million of shares in the first nine months of 2020 and 2019, respectively. Cash proceeds and tax benefits from stock option exercises provide a portion of the funding for repurchase activity.

The impact on financing cash flows of commercial paper and notes payable issuances and long-term debt borrowings and repayments are shown in the following table:

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Nine Months Ended September 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Net issuances of commercial paper and notes payable | **​** | **​** | **$165.5** | ​ | ​ | ​ | $149.5 | ​ | ​ | **​** | **$16.0** | ​ | ​ |
| Long-term debt borrowings | **​** | **​** | **1,855.9** | ​ | ​ | ​ | - | ​ | ​ | **​** | **1,855.9** | ​ | ​ |
| Long-term debt repayments | **​** | **​** | **(1,570.0)** | ​ | ​ | ​ | (400.6) | ​ | ​ | **​** | **(1,169.4)** | ​ | ​ |

### Liquidity and Capital Resources

We currently expect to fund the cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of September 30, 2020, we had $1,035 million of cash and cash equivalents on hand, of which $218 million was held outside of the U.S. We have increased our available cash on hand during the third quarter to meet current and any future potential operational cash needs as a result of COVID-19 pandemic. We will continue to evaluate our cash position in light of future developments.

As of September 30, 2020, we have a $2.0 billion multi-year credit facility which expires in November 2022. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At the end of the third quarter of 2020, we had $225 million of commercial paper outstanding under our U.S. program. There were no borrowings under our credit facility as of September 30, 2020 or 2019. As of September 30, 2020, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

As of September 30, 2020, we have a $500 million 364-day revolving credit agreement to be used for general corporate purposes with a diverse syndicate of banks to provide for further liquidity over the next twelve months in response to the coronavirus pandemic. There were no borrowings under this revolving credit agreement as of September 30, 2020. In addition, we executed a $305 million term credit agreement in April 2020, which we drew on and repaid $303 million during the second quarter of 2020.

Our long-term debt issuance and repayment activity through the first nine months of 2020 and 2019 is discussed in the Cash Flows – Financing Activities section of this MD&A.

We are in compliance with our debt covenants and believe we have sufficient borrowing capacity to meet our foreseeable operating activities, as needed.

The schedule of contractual obligations included in the Financial Position and Liquidity section of our Form 10-K for the year ended December 31, 2019 disclosed total notes payable and long-term debt due within one year of $326 million. As of September 30, 2020, the total notes payable and long-term debt due within one year decreased to $22 million. The commercial paper outstanding as of September 30, 2020 increased to $225 million. The commercial paper outstanding as of December 31, 2019 was $55 million.

Our gross liability for uncertain tax positions was $25 million as of September 30, 2020 and $28 million as of December 31, 2019. We are not able to reasonably estimate the amount by which the liability will increase or decrease over time; however, at this time, we do not expect significant payments related to these obligations within the next year.

### GLOBAL ECONOMIC ENVIRONMENT

### Coronavirus disease 2019 (COVID-19)

In March 2020, the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets, while industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic. As the spread of the pandemic continues, many countries have required companies to limit or suspend business operations and have implemented travel restrictions. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world. We anticipate continued adverse impacts and disruptions in our restaurant, hospitality and entertainment-related business operations, with modest impact on our Industrial segment businesses and limited or no adverse impacts on certain other parts of our business from COVID-19 restrictions; certain of our business will benefit from increased cleaning and sanitizing product demand. The ongoing effects of the global COVID-19 outbreak could result in a global recession.

We anticipate a reduction to our 2020 results of operations and operating cash flows versus prior year levels due to lower market demand, but we are not yet able to estimate the full impact of the coronavirus outbreak as it continues to spread globally. While we continue to provide cleaning, disinfection programs and increased sanitizing protocols in response to the COVID-19 pandemic in healthcare, quick-service and food and beverage plant customers, we anticipate products and services provided to the full-service restaurant, hospitality, lodging and entertainment industries will continue to be negatively impacted for the remainder of the year due to the regulatory and organizational mandates that have been put in place. We have taken, and are continuing to take, steps to reduce costs, including reductions in capital expenditures, as well as other ongoing cost initiatives.

### Global Economies

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results.

Argentina has continued to experience negative economic trends, evidenced by multiple periods of increasing inflation rates, devaluation of the peso, and increasing borrowing rates. Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During the first nine months of 2020, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina at the end of the third quarter represented less than 1% of our consolidated assets.

### Brexit Referendum

Effective January 31, 2020, the U.K. left the European Union. The U.K.’s relationship with the EU will no longer be governed by the EU Treaties, but instead by the terms of the Withdrawal Agreement agreed between the U.K. and the EU in late 2019. The Withdrawal Agreement provides for a “transition” period, which commenced the moment the U.K. left the EU and is currently set to end on December 31, 2020. At the end of the transition period, there may be significant changes to the U.K.’s business environment. While the effects of Brexit will depend on any agreements the U.K. makes to retain access to EU markets or the failure to reach such agreements, the uncertainties created by Brexit, any resolution between the U.K. and EU countries or the failure to reach any such resolutions, could adversely affect our relationships with customers, suppliers and employees and could adversely affect our business.

### NEW ACCOUNTING PRONOUNCEMENTS

For information on new accounting pronouncements, refer to Note 18 to the Consolidated Financial Statements.

### NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

- Fixed currency sales
- Acquisition adjusted fixed currency sales
- Adjusted cost of sales
- Adjusted gross margin
- Fixed currency operating income
- Fixed currency operating income margin
- Adjusted operating income
- Adjusted operating income margin
- Adjusted fixed currency operating income
- Adjusted fixed currency operating income margin
- Acquisition adjusted fixed currency operating income
- Acquisition adjusted fixed currency operating income margin
- Adjusted interest expense, net
- EBITDA
- Adjusted tax rate
- Adjusted net income attributable to Ecolab
- Adjusted diluted EPS

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for cost of sales, gross margin and operating income exclude the impact of special (gains) and charges, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted EPS further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including noncontrolling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-Q are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2020.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, exclude the results of our divested businesses from the twelve months prior to divestiture.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP, and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts.

### FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the effects of the COVID-19 pandemic; expectations concerning timing, amount and type of restructuring costs and savings from restructuring activities; tax deductibility of goodwill; capital investments and acquisitions; amortization expense; non-performance of financial counterparties; payments and contributions to pension and postretirement health care benefit plans; the impact of lawsuits, claims and environmental matters; impact of new accounting pronouncements; cash flows, borrowing capacity and funding of cash requirements; payments related to uncertain tax positions; and implementation of ERP system upgrade.

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof) or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. In particular, the effects of the COVID-19 pandemic depend on numerous factors, including the extent to which the COVID-19 pandemic continues to spread, actions by various governments to address the COVID-19 pandemic, such as stay-at-home orders and restrictions on gatherings and travel, scientific advances to combat COVID-19, the time it takes for our key end markets to recover, the financial health of our customers and channel partners, potential supply chain disruptions, and the health and welfare of our employees; and the ultimate results of any restructuring and business improvement actions, including cost synergies, depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring and other business improvement initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made.

Some of the factors which could cause results to differ materially from those expressed in any forward-looking statements are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the effects of the coronavirus (COVID-19) pandemic; the vitality of the markets we serve; the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk and reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar; our ability to execute key business initiatives, including restructurings and our Enterprise Resource Planning system upgrades; potential information technology infrastructure failures or breaches in data security; potential to incur significant tax liabilities or indemnification liabilities relating to the separation and split-off of our ChampionX business; our ability to attract, retain and develop high caliber management talent to lead our business; our ability to successfully compete with respect to value, innovation and customer support; exposure to global economic, political and legal risks related to our international operations; difficulty in procuring raw materials or fluctuations in raw material costs; pressure on operations from consolidation of customers or vendors; the costs and effects of complying with laws and regulations, including those relating to the environment, to the manufacture, storage, distribution, sale and use of our products and to labor and employment, as well as to the conduct of our business generally; restraints on pricing flexibility due to contractual obligations; our ability to acquire complementary businesses and to effectively integrate such businesses; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with the covenants that apply to our indebtedness; public health outbreaks, epidemics or pandemics, such as the current outbreak of COVID-19; potential losses arising from the impairment of goodwill or other assets; potential chemical spill or release; the occurrence of litigation or claims, including class action lawsuits; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism;

natural or man-made disasters; water shortages; severe weather conditions; and other uncertainties or risks reported from time to time in our reports to the SEC. There can be no assurances that our earnings levels will meet investors’ expectations. Except as may be required under applicable law, we do not undertake, and expressly disclaim, any duty to update our Forward-Looking Statements.

## Market risk

As filed, 555 characters.

We use foreign currency forward contracts, interest rate swap agreements and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in our foreign operations. We do not hold derivative financial instruments of a speculative nature or for trading purposes. For a more detailed discussion of derivative instruments, refer to Note 9, entitled “Derivatives and Hedging Transactions”, of the consolidated financial statements located under Part I, Item 1 of this quarterly report on Form 10-Q.

## Controls and procedures

As filed, 1,345 characters.

As of September 30, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including the Chairman of the Board and Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our Chairman of the Board and Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures are effective.

During the period July 1 through September 30, 2020, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. We also made changes to our system in order to support our separation of the ChampionX business. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

## Risk factors

As filed, 37,494 characters.

In this item 1A, we identify important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q. See the section entitled Forward-Looking Statements located on page 53 of this Form 10-Q. We may also refer to such disclosure to identify factors that may cause results to differ from those expressed in other forward-looking statements made in oral presentations, including telephone conferences and/or webcasts open to the public.

The risk factors set forth below are, with the exception of limited updates to the risk factor relating to our outstanding indebtedness, the same as the risk factors disclosed under the heading “Item 1A. Risk Factors” in Exhibit 99.1 to our current report on Form 8-K filed with the SEC on September 25, 2020 (the “September 25 8-K”), which we filed to reflect certain retrospective revisions relating to the ChampionX business as discontinued operations and to reflect the changes in our reportable segments described in Note 16 entitled “Operating Segments” in the Condensed Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. The risk factors set forth below update and supersede the risk factors disclosed in Item 1A of our annual report on Form 10-K for the year ended December 31, 2019, in Part II, Item 1A of our quarterly reports on Form 10-Q for the quarterly periods ended March 31, 2020 and June 30, 2020, and under the heading “Item 1A. Risk Factors” in Exhibit 99.1 to the September 25 8-K.

***The COVID-19 pandemic has materially and adversely impacted, and we expect will continue to materially and adversely impact, our business.***

The COVID-19 pandemic has had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) have significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. Prolonged economic weakness, including an extended period of elevated levels of unemployment in the key countries we serve, could further reduce discretionary consumer spending and consumer confidence, which could have a further adverse effect on our business and results of operations. We expect the full impact of the COVID-19 pandemic, including the extent of its effect on our business, results of operations and financial condition, to be dictated by future developments which remain uncertain and cannot be predicted, such as its duration and spread, the success of efforts to contain it, the possibility of subsequent widespread outbreaks and the impact of actions taken in response. In addition to the reduction in the demand for our products and services, the COVID-19 pandemic has had, and we expect will continue to have, certain negative impacts on our business, including, but not limited to, the following:

- We rely on a global workforce, and our business demands we take measures to protect the health and safety of our employees, customers and others with whom we do business, while continuing to effectively manage our employees and maintain business operations. We have taken additional measures and incurred additional expenses to protect the health and safety of our employees to comply with applicable government requirements and safety guidance. Additionally, our business operations may be disrupted if a significant portion of our workforce is unable to work safely and effectively due to illness, quarantines, government actions or other restrictions or measures responsive to the pandemic, or if members of senior management or our Board of Directors are unable to perform their duties for an extended period of time. Measures taken across our business operations to address health and safety may not be sufficient to prevent the spread of COVID-19 among our employee base, customers and others. Therefore, we could face operational disruptions and incur additional expenses, including devoting additional resources to assisting employees diagnosed with COVID-19 and further changing health and safety protocols and processes, that could adversely affect our business and results of operations.
- A significant number of our employees, as well as customers and others with whom we do business, continue to work remotely in response to the COVID-19 pandemic. Our business operations may be disrupted, and we may experience increased risk of adverse effects to our business, if a significant portion of our workforce or certain business operations are negatively impacted as a result of remote work arrangements, including due to cybersecurity risks or other disruption to our technology infrastructure. Further, if our key operating facilities experience closures or worker shortages as a result of COVID-19, whether temporary or sustained, our business operations could be significantly disrupted.
- Cost management and various cost-containment actions implemented across our business in response to the COVID-19 pandemic could hinder execution of our business strategy, including deferral of planned capital expenditures, and could adversely affect our business and results of operations.
- We cannot be certain that loss or delay in the collection of accounts receivable will not have a material adverse effect on our results of operations and financial condition.

### Our results depend upon the continued vitality of the markets we serve.

Economic downturns, and in particular downturns in our larger markets including the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining and steel industries, can adversely impact our end-users. This year we are experiencing the negative impact of the COVID-19 pandemic on the demand for our products and services provided to customers in the full-service restaurant, hospitality, lodging and entertainment industries. In recent years, the weaker global economic environment, particularly in Europe, has also negatively impacted certain of our end-markets. During these periods of weaker economic activity, our customers and potential customers may reduce or discontinue their volume of purchases of cleaning and sanitizing products and water treatment and process chemicals, which has had, and may continue to have, a material adverse effect on our business, financial condition, results of operation or cash flows.

### Our results are impacted by general worldwide economic factors.

Economic factors such as the worldwide economy, capital flows, interest rates and currency movements, including, in particular, our exposure to foreign currency risk, have affected our business in the past and may have a material adverse impact on our business in the future. For example, in 2011 and 2012, the European Union’s sovereign debt crisis negatively impacted economic activity in that region as well as the strength of the euro versus the U.S. dollar. Additionally, the June 2016 Brexit vote resulted in a sharp decline in the value of the British pound, as compared to the U.S. dollar and other currencies, and has caused increased fluctuations and unpredictability in foreign currency exchange rates. The possibility for referendum by other EU member states may lead to further market volatility. Other regions of the world, including emerging market areas, also expose us to foreign currency risk. As a result of increasing currency controls, importation restrictions, workforce regulations, pricing constraints and local capitalization requirements, we deconsolidated our Venezuelan subsidiaries effective as of the end of the fourth quarter of 2015. Prior to deconsolidation, across the second through fourth quarters of 2015, we devalued our Venezuelan bolivar operations within various of our operating segments, including Water, Paper, Food & Beverage and Institutional. Similar currency devaluations, credit market disruptions or other economic turmoil in other countries could have a material adverse impact on our consolidated results of operations, financial position and cash flows by negatively impacting economic activity, including in our key end-markets, and by further weakening the local currency versus the U.S. dollar, resulting in reduced sales and earnings from our foreign operations, which are generated in the local currency, and then translated to U.S. dollars.

***If we are unsuccessful in executing on key business initiatives, including restructurings and our Enterprise Resource Planning (“ERP”) system upgrades, our business could be materially and adversely affected.***

We continue to execute key business initiatives, including restructurings and investments to develop business systems, as part of our ongoing efforts to improve our efficiency and returns. In particular, we are undertaking the Accelerate 2020 plan to simplify and automate processes and tasks, reduce complexity and management layers, consolidate facilities and focus on key long-term growth areas by leveraging technology and structural improvements as discussed under Note 2 entitled “Special (Gains) and Charges” of this Form 10-Q.

Additionally, we are continuing implementation of our ERP system upgrades, which are expected to continue in phases over the next several years. These upgrades, which include sales, supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades involve complex business process design and a failure of certain of these processes could result in business disruption. We also made changes to our system in order to support our separation of the ChampionX business. If the projects in which we are investing or the initiatives which we are pursuing are not successfully executed, our consolidated results of operations, financial position or cash flows could materially and adversely be affected.

***We may be subject to information technology system failures, network disruptions and breaches in data security.***

We rely to a large extent upon information technology systems and infrastructure to operate our business. The size and complexity of our information technology systems make them potentially vulnerable to failure, malicious intrusion and random attack. Acquisitions have resulted in further de-centralization of systems and additional complexity in our systems infrastructure. Likewise, data security breaches by employees or others with permitted access to our systems may pose a risk that sensitive data may be exposed to unauthorized persons or to the public. While we have invested in protection of data and information technology, there can be no assurance that our efforts will prevent failures, cybersecurity attacks or breaches in our systems that could cause reputational damage, business disruption or legal and regulatory costs; could result in third-party claims; could result in compromise or misappropriation of our intellectual property, trade secrets or sensitive information; or could otherwise adversely affect our business. Certain of our customer offerings include digital components, such as remote monitoring of certain customer operations. A breach of those remote monitoring systems could expose customer data giving rise to potential third-party claims and reputational damage. There may be other related challenges and risks as we complete implementation of our ERP system upgrade.

***If the separation and split-off of our Upstream Energy business or certain internal transactions undertaken in anticipation of the divestiture are determined to be taxable in whole or in part, we and our stockholders may incur significant tax liabilities.***

In connection with the separation and split-off of our Upstream Energy business that was consummated on June 3, 2020, we obtained opinions of outside tax counsel that the merger and exchange offer will qualify as tax-free transactions to us and our stockholders, except to the extent that cash was paid to Ecolab stockholders in lieu of fractional shares. We have not sought or obtained a ruling from the Internal Revenue Service (IRS) on the tax consequences of these transactions. An opinion of counsel is not binding on the IRS or the courts, which may disagree with the opinion. Even if the merger and exchange offer otherwise qualified as tax-free transactions, they may become taxable to us if certain events occur that affect either Ecolab or ChampionX Corporation. While ChampionX Corporation has agreed not to take certain actions that could cause the transactions not to qualify as tax-free transactions and is generally obligated to indemnify us against any tax consequences if it breaches this agreement, the potential tax liabilities could have a material adverse effect on us if we were not entitled to indemnification or if the indemnification obligations were not fulfilled. If the merger or exchange offer were determined to be taxable, we could be subject to a substantial tax liability, and each U.S. holder of our common stock who participated in the exchange offer could be treated as exchanging the Ecolab shares surrendered for ChampionX Corporation shares in a taxable transaction.

***Potential indemnification liabilities pursuant to the separation and split-off of our Upstream Energy business could materially and adversely affect our business and financial statements.***

With respect to the separation and subsequent split-off of our Upstream Energy business, we entered into a separation and distribution agreement with ChampionX Holding Inc. and ChampionX Corporation (f/k/a Apergy Corporation and taken together with ChampionX Holding Inc., “ChampionX”) as well as certain other agreements to govern the separation and related transactions and our relationship with ChampionX going forward. These agreements provide for specific indemnity and certain other obligations of each party and could lead to disputes between ChampionX and us. If we are required to indemnify ChampionX under the circumstances set forth in these agreements, we may be subject to substantial related liabilities. In addition, with respect to the liabilities for which ChampionX has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against ChampionX will be sufficient to protect us against the full amount of such liabilities, or that ChampionX will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our business and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

### We depend on key personnel to lead our business.

Our continued success will largely depend on our ability to attract, retain and develop a high caliber of talent and on the efforts and abilities of our executive officers and certain other key employees, particularly those with sales and sales management responsibilities to drive business growth, development and profitability. As we continue to grow our business, make acquisitions, expand our geographic scope and offer new products and services, we need the organizational talent necessary to ensure effective succession for executive officer and key employee roles in order to meet the growth, development and profitability goals of our business. Our operations could be materially and adversely affected if for any reason we were unable to attract, retain or develop such officers or key employees and successfully execute organizational change and management transitions at leadership levels.

***Our growth depends upon our ability to successfully compete with respect to value, innovation and customer support.***

We have numerous global, national, regional and local competitors. Our ability to compete depends in part on providing high quality and high value-added products, technology and service. We must also continue to identify, develop and commercialize innovative, profitable and high value-added products for niche applications and commercial digital applications. We have made significant investments in commercial digital product offerings, and our culture and expertise must continue to evolve to develop, support and profitably deploy commercial digital offerings, which are becoming an increasingly important part of our business. There can be no assurance that we will be able to accomplish our technology development goals or that technological developments by our competitors will not place certain of our products, technology or services at a competitive disadvantage in the future. In addition, certain of the new products that we have under development will be offered in markets in which we do not currently compete, and there can be no assurance that we will be able to compete successfully in those new markets. If we fail to introduce new technologies or commercialize our digital offerings on a timely and profitable basis, we may lose market share and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

***Our significant non-U.S. operations expose us to global economic, political and legal risks that could impact our profitability.***

We have significant operations outside the United States, including joint ventures and other alliances. We conduct business in approximately 170 countries and, in 2019, approximately 46% of our net sales originated outside the United States. There are inherent risks in our international operations, including:

- exchange controls and currency restrictions;
- currency fluctuations and devaluations;
- tariffs and trade barriers;
- export duties and quotas;
- changes in the availability and pricing of raw materials, energy and utilities;
- changes in local economic conditions;
- changes in laws and regulations, including the imposition of economic or trade sanctions affecting international commercial transactions;
- impact from Brexit and the possibility of similar events in other EU member states;
- difficulties in managing international operations and the burden of complying with international and foreign laws;
- requirements to include local ownership or management in our business;
- economic and business objectives that differ from those of our joint venture partners;
- exposure to possible expropriation, nationalization or other government actions;
- restrictions on our ability to repatriate dividends from our subsidiaries;
- unsettled political conditions, military action, civil unrest, acts of terrorism, force majeure, war or other armed conflict; and
- countries whose governments have been hostile to U.S.-based businesses.

Effective January 31, 2020, the U.K. has formally left the European Union. The U.K.’s relationship with the EU will no longer be governed by the EU Treaties, but instead by the terms of the Withdrawal Agreement agreed between the U.K. and the EU in late 2019. The Withdrawal Agreement provides for a “transition” period, which commenced the moment the U.K. left the EU and is currently set to end on December 31, 2020. At the end of the transition period, there may be significant changes to the U.K.’s business environment. While the effects of Brexit will depend on any agreements the U.K. makes to retain access to EU markets or the failure to reach such agreements, the uncertainties created by Brexit, any resolution between the U.K. and EU countries or the failure to reach any such resolutions, could adversely affect our relationships with customers, suppliers and employees and could have a material adverse effect our business.

In addition, changes in U.S. or foreign government policy on international trade, including the imposition or continuation of tariffs, could materially and adversely affect our business. In 2018, the U.S. imposed tariffs on certain imports from China and other countries, resulting in retaliatory tariffs by China and other countries. While the U.S. and China signed what is being known as the Phase One Deal in January 2020, which included the suspension and rollback of tariffs, any new tariffs imposed by the U.S., China or other countries or any additional retaliatory measures by any of these countries, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

Also, because of uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights, we face risks in some countries that our intellectual property rights and contract rights would not be enforced by local governments. We are also periodically faced with the risk of economic uncertainty, which has impacted our business in some countries. Other risks in international business also include difficulties in staffing and managing local operations, including managing credit risk to local customers and distributors.

Further, our operations outside the United States require us to comply with a number of United States and international regulations, including anti-corruption laws such as the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as U.S. and international economic sanctions regulations. We have internal policies and procedures relating to such regulations; however, there is risk that such policies and procedures will not always protect us from the misconduct or reckless acts of employees or representatives, particularly in the case of recently acquired operations that may not have significant training in applicable compliance policies and procedures. Violations of such laws and regulations could result in disruptive investigations, significant fines and sanctions, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social, legal and political conditions. We may not continue to succeed in developing and implementing policies and strategies that are effective in each location where we do business, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Our results could be materially and adversely affected by difficulties in securing the supply of certain raw materials or by fluctuations in the cost of raw materials.***

The prices of raw materials used in our business can fluctuate from time to time, and in recent years we have experienced periods of increased raw material costs. Changes in raw material prices, unavailability of adequate and reasonably priced raw materials or substitutes for those raw materials, or the inability to obtain or renew supply agreements on favorable terms can materially and adversely affect our consolidated results of operations, financial position or cash flows. In addition, volatility and disruption in economic activity and conditions could disrupt or delay the performance of our suppliers and thus impact our ability to obtain raw materials at favorable prices or on favorable terms, which may materially and adversely affect our business.

***Consolidation of our customers and vendors could materially and adversely affect our results.***

Customers and vendors in the foodservice, hospitality, travel, healthcare, food processing, refining and pulp and paper industries, as well as other industries we serve, have consolidated in recent years and that trend may continue. This consolidation could have a material adverse impact on our ability to retain customers and on our pricing, margins and consolidated results of operations.

***Our business depends on our ability to comply with laws and governmental regulations, and we may be materially and adversely affected by changes in laws and regulations.***

Our business is subject to numerous laws and regulations relating to the environment, including evolving climate change standards, and to the manufacture, storage, distribution, sale and use of our products as well as to the conduct of our business generally, including employment and labor laws. Compliance with these laws and regulations exposes us to potential financial liability and increases our operating costs. Regulation of our products and operations continues to increase with more stringent standards, causing increased costs of operations and potential for liability if a violation occurs. The potential cost to us relating to environmental and product registration laws and regulations is uncertain due to factors such as the unknown magnitude and type of possible contamination and clean-up costs, the complexity and evolving nature of laws and regulations and the timing and expense of compliance. Changes to current laws (including tax laws), regulations and policies could impose new restrictions, costs or prohibitions on our current practices which would have a material adverse effect on our consolidated results of operations, financial position or cash flows. Changes to labor and employment laws and regulations, as well as related rulings by courts and administrative bodies, could materially and adversely affect our operations and expose us to potential financial liability.

### We enter into multi-year contracts with customers that could impact our results.

Our multi-year contracts with some of our customers include terms affecting our pricing flexibility. There can be no assurance that these restraints will not have a material adverse impact on our margins and consolidated results of operations.

***If we are unsuccessful in integrating acquisitions, our business could be materially and adversely affected.***

As part of our long-term strategy, we seek to acquire complementary businesses. There can be no assurance that we will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses into existing businesses. If the underlying business performance of such acquired businesses deteriorates, the expected synergies from such transactions do not materialize or we fail to successfully integrate new businesses into our existing businesses, our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

***Changes in tax laws and unanticipated tax liabilities could materially and adversely affect the taxes we pay and our profitability.***

We are subject to income and other taxes in the United States and foreign jurisdictions, and our operations, plans and results are affected by tax and other initiatives around the world. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States, including tax reform under the 2017 Tax Cuts and Jobs Act (the “Tax Act”), which includes broad and complex changes to the United States tax code, and the state tax response to the Tax Act, including, but not limited to, variability in our future tax rate. We are also subject to changes in tax law outside the United States. In addition, we are impacted by settlements of pending or any future adjustments proposed by the IRS or other taxing authorities in connection with our tax audits, all of which will depend on their timing, nature and scope. Increases in income tax rates, changes in income tax laws (including regulations which interpret the Tax Act) or unfavorable resolution of tax matters could have a material adverse impact on our financial results.

***Future events may impact our deferred tax position, including the utilization of foreign tax credits and undistributed earnings of international affiliates that are considered to be reinvested indefinitely.***

We evaluate the recoverability of deferred tax assets and the need for deferred tax liabilities based on available evidence. This process involves significant management judgment about assumptions that are subject to change from period to period based on changes in tax laws or variances between future projected operating performance and actual results. We are required to establish a valuation allowance for deferred tax assets if we determine, based on available evidence at the time the determination is made, that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making this determination, we evaluate all positive and negative evidence as of the end of each reporting period. Future adjustments (either increases or decreases), to the deferred tax asset valuation allowance are determined based upon changes in the expected realization of the net deferred tax assets. The realization of the deferred tax assets ultimately depends on the existence of sufficient taxable income in either the carry-back or carry-forward periods under the tax law. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record adjustments to the valuation allowance in future reporting periods. Changes to the valuation allowance or the amount of deferred tax liabilities could have a material adverse effect on our consolidated results of operations or financial position. Further, should we change our assertion regarding the permanent reinvestment of the undistributed earnings of international affiliates, a deferred tax liability may need to be established.

***Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could materially and adversely affect our liquidity and financial results.***

As of September 30, 2020, we had approximately $6.9 billion in outstanding indebtedness, with approximately $0.2 billion in the form of floating rate debt. Our debt level and related debt service obligations may have negative consequences, including:

- requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which reduces the funds we have available for other purposes such as acquisitions and capital investment;
- reducing our flexibility in planning for or reacting to changes in our business and market conditions;
- exposing us to interest rate risk since a portion of our debt obligations are at variable rates. For example, a one percentage point increase in the average interest rate on our floating rate debt at September 30, 2020 would increase future interest expense by approximately $2 million per year; and
- increasing our cost of funds and materially and adversely affecting our liquidity and access to the capital markets should we fail to maintain the credit ratings assigned to us by independent rating agencies.

If we add new debt, the risks described above could increase.

### Severe public health outbreaks may materially and adversely impact our business.

Our business could be adversely affected by the effect of a public health epidemic. Besides the COVID-19 pandemic, the United States and other countries have experienced, and may experience in the future, public health outbreaks such as Zika virus, Avian Flu, SARS and H1N1 influenza. A prolonged occurrence of a contagious disease such as these could result in a significant downturn in the foodservice, hospitality and travel industries and also may result in health or other government authorities imposing restrictions on travel further impacting our end markets. Any of these events could result in a significant drop in demand for some of our products and services and materially and adversely affect our business. Uncertainty with respect to the impact on our financial results of the coronavirus outbreak is discussed further in Management Discussion & Analysis located at Part I, Item 2, of this Form 10-Q under the heading “Global Economic Environment.”

***We incur significant expenses related to the amortization of intangible assets and may be required to report losses resulting from the impairment of goodwill or other assets recorded in connection with the Nalco transaction and other acquisitions.***

We expect to continue to complete selected acquisitions and joint venture transactions in the future. In connection with acquisition and joint venture transactions, applicable accounting rules generally require the tangible and intangible assets of the acquired business to be recorded on the balance sheet of the acquiring company at their fair values. Intangible assets other than goodwill are required to be amortized over their estimated useful lives and this expense may be significant. Any excess in the purchase price paid by the acquiring company over the fair value of tangible and intangible assets of the acquired business is recorded as goodwill. If it is later determined that the anticipated future cash flows from the acquired business may be less than the carrying values of the assets and goodwill of the acquired business, the assets or goodwill may be deemed to be impaired. In this case, the acquiring company may be required under applicable accounting rules to write down the value of the assets or goodwill on its balance sheet to reflect the extent of the impairment. This write-down of assets or goodwill is generally recognized as a non-cash expense in the statement of operations of the acquiring company for the accounting period during which the write down occurs. As of December 31, 2019, we had goodwill of $5.6 billion which is maintained in various reporting units, including goodwill from the Nalco transaction. If we determine that any of the assets or goodwill recorded in connection with the Nalco transaction or any other prior or future acquisitions or joint venture transactions have become impaired, we will be required to record a loss resulting from the impairment. Impairment losses could be significant and could have a material adverse effect on our consolidated results of operations and financial position.

### A chemical spill or release could materially and adversely impact our business.

As a manufacturer and supplier of chemical products, there is a potential for chemicals to be accidentally spilled, released or discharged, either in liquid or gaseous form, during production, transportation, storage or use. Such a release could result in environmental contamination as well as a human or animal health hazard. Accordingly, such a release could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

### Extraordinary events may significantly impact our business.

The occurrence of (a) litigation or claims, (b) the loss or insolvency of a major customer or distributor, (c) repeated or prolonged federal government shutdowns or similar events, (d) war (including acts of terrorism or hostilities which impact our markets), (e) natural or manmade disasters, (f) water shortages or (g) severe weather conditions affecting our operations or industries we serve may have a material adverse effect on our business.

Defense of litigation, particularly certain types of actions such as antitrust, patent infringement, personal injury, product liability and wage hour lawsuits, including class actions and arbitration proceedings, can be costly and time consuming even if ultimately successful, and if not successful could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

While we have a diverse customer base and no customer or distributor constitutes 10 percent or more of our consolidated revenues, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on our consolidated results of operations or cash flows for the affected earnings periods.

Federal government shutdowns can have a material adverse effect on our consolidated results of operations or cash flows by disrupting or delaying new product launches, renewals of registrations for existing products and receipt of import or export licenses for raw materials or products.

War (including acts of terrorism or hostilities), natural or manmade disasters, water shortages or severe weather conditions affecting the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining, steel and other industries can cause a downturn in the business of our customers, which in turn can have a material adverse effect on our consolidated results of operations, financial position or cash flows. In particular, the U.S. Gulf Coast is a region with significant refining, petrochemicals and chemicals operations which provide us raw materials, as well as being an important customer base for our Water and Downstream operating segments. Hurricanes or other severe weather events impacting the Gulf Coast could materially and adversely affect our ability to obtain raw materials at reasonable cost, or at all, and could adversely affect our business with our customers in the region.

Filed Oct 30, 2020.
Source: SEC EDGAR, the filing index for accession 0001558370-20-012094. Last ingested by Listed: Nov 13, 2026, 16:24 ET. No prices; not investment advice.
